Triple‐Negative Breast Cancer (TNBC) is the most aggressive subtype of breast cancer. Even though TNBC patients respond well to chemotherapy, they quickly relapse, resulting in poor prognoses and low survival rates. TNBCs are characterized by an aberrant metabolic phenotype with high metastatic capacity due to reprogramming of metabolic pathways to fulfill their bioenergetics demands.